These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 26601184)

  • 1. Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline.
    Preiss L; Langer JD; Yildiz Ö; Eckhardt-Strelau L; Guillemont JE; Koul A; Meier T
    Sci Adv; 2015 May; 1(4):e1500106. PubMed ID: 26601184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Halting ionic shuttle to disrupt the synthetic machinery-Structural and molecular insights into the inhibitory roles of Bedaquiline towards Mycobacterium tuberculosis ATP synthase in the treatment of tuberculosis.
    Salifu EY; Agoni C; Olotu FA; Dokurugu YM; Soliman MES
    J Cell Biochem; 2019 Sep; 120(9):16108-16119. PubMed ID: 31125144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple Mycobacterial ATP-synthase mutations impedes Bedaquiline binding: Atomistic and structural perspectives.
    Salifu EY; Agoni C; Olotu FA; Soliman MES
    Comput Biol Chem; 2020 Apr; 85():107204. PubMed ID: 31981966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding properties of the anti-TB drugs bedaquiline and TBAJ-876 to a mycobacterial F-ATP synthase.
    Krah A; Grüber G; Bond PJ
    Curr Res Struct Biol; 2022; 4():278-284. PubMed ID: 36186842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
    Chahine EB; Karaoui LR; Mansour H
    Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Perspective of ATP Synthase Inhibitors in the Management of the Tuberculosis.
    Divita KM; Khatik GL
    Curr Top Med Chem; 2021; 21(18):1623-1643. PubMed ID: 34517802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of mycobacterial ATP synthase inhibition by squaramides and second generation diarylquinolines.
    Courbon GM; Palme PR; Mann L; Richter A; Imming P; Rubinstein JL
    EMBO J; 2023 Aug; 42(15):e113687. PubMed ID: 37377118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re-Understanding the Mechanisms of Action of the Anti-Mycobacterial Drug Bedaquiline.
    Sarathy JP; Gruber G; Dick T
    Antibiotics (Basel); 2019 Dec; 8(4):. PubMed ID: 31835707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of M. tuberculosis and human ATP synthase by BDQ and TBAJ-587.
    Zhang Y; Lai Y; Zhou S; Ran T; Zhang Y; Zhao Z; Feng Z; Yu L; Xu J; Shi K; Wang J; Pang Y; Li L; Chen H; Guddat LW; Gao Y; Liu F; Rao Z; Gong H
    Nature; 2024 Jul; 631(8020):409-414. PubMed ID: 38961288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TBAJ-876 Retains Bedaquiline's Activity against Subunits c and ε of
    Sarathy JP; Ragunathan P; Shin J; Cooper CB; Upton AM; Grüber G; Dick T
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
    Worley MV; Estrada SJ
    Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?
    Field SK
    Ther Adv Chronic Dis; 2015 Jul; 6(4):170-84. PubMed ID: 26137207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ionophoric effects of the antitubercular drug bedaquiline.
    Hards K; McMillan DGG; Schurig-Briccio LA; Gennis RB; Lill H; Bald D; Cook GM
    Proc Natl Acad Sci U S A; 2018 Jul; 115(28):7326-7331. PubMed ID: 29941569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging opportunities of exploiting mycobacterial electron transport chain pathway for drug-resistant tuberculosis drug discovery.
    Roy KK; Wani MA
    Expert Opin Drug Discov; 2020 Feb; 15(2):231-241. PubMed ID: 31774006
    [No Abstract]   [Full Text] [Related]  

  • 16. Interpretation of the mechanism of action of antituberculosis drug bedaquiline based on a novel two-ion theory of energy coupling in ATP synthesis.
    Nath S
    Bioeng Transl Med; 2019 Jan; 4(1):164-170. PubMed ID: 30680327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variations of the Mycobacterium abscessus F-ATP synthase subunit a-c interface alter binding and potency of the anti-TB drug bedaquiline.
    Krah A; Ragunathan P; Bond PJ; Grüber G
    Biochem Biophys Res Commun; 2024 Jan; 690():149249. PubMed ID: 38000294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A tale of two inhibitors: diarylquinolines and squaramides.
    Chen J; Ekiert DC
    EMBO J; 2023 Aug; 42(15):e114912. PubMed ID: 37435707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bedaquiline - The first ATP synthase inhibitor against multi drug resistant tuberculosis.
    Lakshmanan M; Xavier AS
    J Young Pharm; 2013 Dec; 5(4):112-5. PubMed ID: 24563587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unique structural and mechanistic properties of mycobacterial F-ATP synthases: Implications for drug design.
    Kamariah N; Ragunathan P; Shin J; Saw WG; Wong CF; Dick T; Grüber G
    Prog Biophys Mol Biol; 2020 May; 152():64-73. PubMed ID: 31743686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.